Lisa Cook sues Trump over firing attempt, emergency hearing set
In a recent transaction, Broadwood Partners, L.P., a significant shareholder in STAAR Surgical Co. (NASDAQ:STAA), acquired a substantial amount of the company’s common stock. According to a regulatory filing, Broadwood Partners purchased shares valued at approximately $2.4 million over two separate transactions. The purchases come as STAAR’s stock has declined over 53% in the past year, though InvestingPro analysis shows the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 5.23.
On March 21, 2025, Broadwood Partners acquired 102,400 shares at a weighted average price of $17.7397 per share, with prices ranging from $17.665 to $17.74. This transaction increased their total holdings to 12,285,395 shares. Subsequently, on March 25, 2025, they purchased an additional 34,296 shares at a weighted average price of $17.4416 per share, with prices ranging from $17.26 to $17.49, bringing their total holdings to 12,319,691 shares. These purchases occurred as eight analysts revised their earnings expectations downward, with InvestingPro data revealing expectations of sales decline in the current year.
These transactions reflect Broadwood Partners’ continued investment in STAAR Surgical, a company known for its ophthalmic goods. The purchases were made through Broadwood Capital, Inc., the general partner of Broadwood Partners, with Neal C. Bradsher, President of Broadwood Capital, involved in the transactions. Despite current challenges, STAAR maintains a Fair financial health rating according to InvestingPro’s comprehensive analysis, which includes over 30 key financial metrics and valuable investment insights available to subscribers.
In other recent news, STAAR Surgical has been navigating a series of executive changes and financial challenges. The company reported fourth-quarter 2024 results that fell short of expectations, leading to adjustments in analyst ratings and price targets. Jefferies downgraded STAAR Surgical’s stock, reducing the price target to $18 from $60, citing uncertainties in the Chinese market and unclear distributor performance. Similarly, Stifel cut its price target to $20 from $38, maintaining a Buy rating but expressing concerns over inventory levels in China.
Canaccord Genuity also lowered its price target to $17, retaining a Hold rating while noting the company’s low valuation compared to peers. Piper Sandler maintained a Neutral rating with a $16 price target, highlighting executive changes, including the departure of CFO Patrick Williams and the interim appointment of Deborah Andrews. BTIG also maintained a Neutral rating, focusing on the leadership reshuffle following Stephen Farrell’s appointment as CEO.
Despite internal efforts to manage costs and improve financial performance, STAAR Surgical’s future revenue growth remains uncertain, especially with the lack of reaffirmed fiscal year 2025 guidance. Analyst firms have expressed caution, with some suggesting potential investor hesitation due to these ongoing challenges. As STAAR Surgical works through these developments, the company is expected to focus on stabilizing its operations and addressing market uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.